AbGn-207

Therapeutic Area

Product Overview
AbGn-207, the next generation of AbGn-107, maintains the format of antibody-drug conjugate with better safety. The alterations include the modification of the antibody main frame to facilitate homogeneous drug conjugation, the utilization of a new linker to improve its stability, and a cytotoxic payload with different mechanism of action to enhance its efficacy. This second generation ADC is expected to be an effective pharmaceutical in clinical, and to benefit a broader patient population in the near future.

The preclinical production of AbGn-207 is planned in Q2 of 2020, and Q3 of 2021 is the target for an Investigational New Drug (IND) application filing with the U.S. FDA.

Indication

GI Tumors

1

  • PRECLINAICAL

  • PHASE I

  • PHASE IIA

  • PHASE IIB

  • PHASE III

  • MARKET